CF Exacerbation

Presentation


Diagnosis is clinical and based on change from baseline. Common findings include:

  • Increased cough
  • Increased sputum production or change in sputum appearance
  • Dyspnea or reduced exercise tolerance
  • Fatigue
  • Reduced appetite or weight loss
  • Increased respiratory rate
  • Hemoptysis
  • Decline in spirometry, especially FEV1, if available

DDx


Not all respiratory worsening in CF is a routine pulmonary exacerbation. Consider:

  • Community-acquired pneumonia
  • Pneumothorax
  • Hemoptysis from bronchial artery bleeding
  • Viral respiratory infection
  • Allergic bronchopulmonary aspergillosis (ABPA)
  • Nontuberculous mycobacterial disease
  • Pulmonary embolism in the right setting

Eval & Workup


Early data to review

  • Baseline FEV1 and prior trend
  • Prior sputum microbiology
  • Prior antibiotic response
  • Antibiotic allergies
  • Prior respiratory complications
  • Baseline gas exchange or bicarbonate if chronic hypercapnia is a concern

Initial Eval

  • CBC and basic chemistries
  • Sputum culture, with fungal or AFB studies when indicated
  • Viral testing, including influenza and COVID when appropriate
  • Chest x-ray to look for alternative pathology such as pneumothorax or focal pneumonia

Management


  • Continue chronic CF regimen
  • Continue CFTR-directed therapy
  • Airway clearance
    • Chest physiotherapy
    • Percussion vest
    • Oscillatory devices such as Acapella
    • Mobilization and exercise as tolerated
  • Dornase alfa BID
  • Hypertonic saline nebs QID
  • Bronchodilators
    • Before airway clearance sessions
    • Before hypertonic saline or other inhaled therapies if those trigger bronchospasm
    • As rescue therapy in patients with airway hyperreactivity
    • In patients who report clear symptomatic benefit
  • Abx
    • MSSA: IV = cefazolin or nafcillin, PO = bactrim, dox, augmentin
    • MRSA: Vanc, linezolid, ceftaroline
    • Pseudomonas: zosyn, cefepime, ceftazadime, meropenem
      • Depending on severity may add 2nd agent: cipro/levo, tobramycin, amikacin
    • Duration: 10-14 days
  • Steroids
    • Not routinely reccomended
    • May have role if clear asthma physiology or ABPA
  • Nutrition & GI care
    • Nutrition consult
    • Pancreatic enzymes and fat soluble vitamins
    • Bowel regimen

Antibiotics for CF Flare

Organism IV Options Oral Options (mild) Notes
MSSA Cefazolin
Nafcillin
TMP-SMX
Doxycycline
Amox-clav
Common in CF
MRSA Vancomycin
Linezolid
Ceftaroline
Linezolid Monitor CBC if prolonged
Pseudomonas Pip-tazo
Cefepime
Ceftazidime
Meropenem
Imipenem
Ciprofloxacin
Levofloxacin
May add aminoglycoside if severe
MSSA + Pseudomonas Antipseudomonal regimen Avoid ceftazidime alone
MRSA + Pseudomonas Antipseudomonal +
Vancomycin or Linezolid
Often 2–3 drug regimen